Where is gilteritinib produced?

Gilteritinib is a small molecule FLT3/AXL dual inhibitor. Genitinibis indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia(AML) who have a FLT3 mutation detected by an FDAapproved test. The ADMIRAL study showed that compared with salvage chemotherapy for relapsed and refractory (R/R) AML, giltinib had longer overall survival and higher response rate.

Gilteritinib(gilteritinib) is produced by JapanAstellas Pharma, Inc. .An anti-tumor drug synthesized and developed,Giritinib (XOS) was released on September 21, 2018 PATA)obtained marketing approval in Japan,2018Year11Month28Nikkei The U.S. FDA was approved for marketing on 2021 year1 month31 and was approved for marketing by the China Food and Drug Administration. However, currently It has not been included in the medical insurance and cannot be reimbursed. The current domestic retail price40mg*21tablets*2board258,000yuan. There are also generic versions of Giritinib. The version currently on the market is the Lao version. The retail price of 40mg90 tablets is around 4000yuan.

Patients who received Genitinib developed symptoms of differentiation syndrome, which may be fatal or life-threatening if left untreated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain or peripheral edema, hypotension, or renal insufficiency. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptoms resolve. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.